BACKGROUND: Lung adenocarcinoma in the young is a rare entity, and the oncogenic genetic alterations (GAs) and clinical characteristics associated with this disease are poorly understood. Conversely, it has been demonstrated that young age at diagnosis defines unique biology in other cancers. For this report, the effects of young age on lung adenocarcinoma are reported. METHODS: The authors retrospectively screened 1746 consecutive patients who were diagnosed with stage I through IV adenocarcinoma between 2009 and 2015 and identified 81 who were aged 40 years or younger at diagnosis. The clinical and genetic characteristics of this younger population were analyzed. RESULTS: Of the 81 younger patients identified, 36 (44%) were men, 36 (44%) were never smokers, and the median age was 36 years (range, 26-40 years). Thirty-three patients (41%) harbored anaplastic lymphoma kinase (ALK) translocations, 24 (30%) had epidermal growth factor receptor (EGFR) mutations, and 2 (2%) had v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations. Rare oncogenic GAs also were studied in patients who had wild-type ALK/EGFR/ KRAS adenocarcinoma, including 4 patients with HER2 mutations, 2 with Ret proto-oncogene (RET) translocations, and 2 with ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) translocations. Notably, oncogenic GAs (P < .001), ALK (P < .001) and ROS1 (P 5 .033) translocations, and HER2 mutations (P < .001) were associated with young age, and a similar trend was observed for RET translocations (P 5
INTRODUCTION
The development of molecularly targeted therapy in genomically defined subsets of patients has recently revolutionized treatment of nonsmall cell lung cancer (NSCLC). The identification of epidermal growth factor receptor (EGFR) mutations [1] [2] [3] and anaplastic lymphoma kinase (ALK) gene fusions 4 are classic examples of oncogenic genetic alterations (GAs) that confer sensitivity to matched targeted therapies. Patients with EGFR mutations or ALK translocations have experienced a significant survival benefit from approved targeted agents (erlotinib, gefitinib, and afatinib for EGFR and crizotinib and alectinib for ALK). The subsequent discovery of Ret proto-oncogene (RET) and ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) translocations as potentially treatable targets suggested that several chromosomal translocations and corresponding gene fusions may serve as a driving force for NSCLC. [5] [6] [7] [8] In comprehensive genomic profiling analysis, driver GAs have been identified in approximately 50% of lung adenocarcinomas, including EGFR, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), ALK, B-raf proto-oncogene, serine/threonine kinase (BRAF), human epidermal growth factor receptor 2 (HER2), RET, and ROS1. [9] [10] [11] NSCLC diagnosed in young patients is relatively rare, 12 and the genomics and clinical characteristics of this population are poorly understood. In contrast, unique disease biology has been demonstrated in other cancers diagnosed at a young age. For example, breast cancer in younger patients has been associated with both an increased frequency of breast cancer gene 1 (BRCA1) and BRCA2 mutations as well as an increased likelihood of HER2 overexpression and triple-negative disease. [13] [14] [15] Colon cancer in the young also reportedly has been associated with higher rates of microsatellite instability and similarly demonstrates more aggressive disease biology. [16] [17] [18] Thus, lung adenocarcinomas emerging in young patients potentially possess unique tumor biology and correlate with oncogenic GAs, although the details remain largely unknown.
In the current study, we performed driver GA analysis mainly focusing on patients with lung adenocarcinoma aged 40 years to elucidate the correlations between young age, other patient characteristics, prognosis, and driver GAs.
MATERIALS AND METHODS

Patients and Samples
We retrospectively screened 1746 consecutive patients who were diagnosed with stage I through IV adenocarcinoma between 2009 and 2015. Eligible individuals were required to have pathologically confirmed lung adenocarcinoma and sufficient tissue for driver GA analysis, including at least EGFR and KRAS mutations. We retrospectively collected the following clinical data: sex, age at diagnosis, smoking history, performance status (PS), TNM stage, and prognosis. Histologic subtypes of lung adenocarcinoma were classified according to the new International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society multidisciplinary classification of lung adenocarcinoma. 19 This study was conducted with approval from the Institutional Review Board of Aichi Cancer Center.
Mutation Analyses of EGFR, KRAS, HER2, and BRAF EGFR mutations (exons 18-21) were identified using the cycleave polymerase chain reaction (PCR) method. HER2 (exon 20), KRAS (exons 2-3) and BRAF mutations (exons [11] [12] [13] [14] [15] were analyzed using fragment analysis, and the results were partly validated with direct sequencing.
Detection of ALK, RET, and ROS1 Fusions ALK fusions were examined by reverse transcriptase PCR (rtPCR), immunohistochemistry (IHC), or fluorescence in situ hybridization (FISH) assays (Vysis ALK Break Apart FISH Probe Kit; Vysis, Inc, Downers Grove, Ill), and a tumor was considered to be ALK positive when at least 2 of the rtPCR, IHC, or FISH tests had positive results, as previously reported. 20, 21 RET and ROS1 fusions were identified by rtPCR, and validated with FISH assays (Dako Sure FISH RET/ROS1 BA P5; Dako, Carpenteria, Calif), which have been previously described. 5, 22 PCR primers for echinoderm microtubule associated protein-like 4 (EML4)-ALK, kinesin family member 5B (KIF5B)-RET, and cluster of differentiation 74 (major histocompatibility complex, class II invariant chain [CD74])-ROS1 fusions are listed in Supporting Table 1 (see online supporting information).
Statistical Analysis
We used Pearson chi-square tests or Fisher exact tests to assess correlations between oncogenic GAs and clinical variables. Survival curves of recurrence-free survival (RFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Differences in survival between the 2 groups were assessed using log-rank tests. Multivariate analyses of RFS and OS were performed using a Cox proportional-hazards model. Statistical analyses were conducted using the JMP statistical software program (version 9; SAS Institute Inc, Cary, NC). All tests were 2-sided, and P values < .05 were considered significant.
RESULTS
Patient Characteristics
Between 2009 and 2015, in total, we screened 1746 consecutive patients who had lung cancer diagnosed as adenocarcinoma at Aichi Cancer Center Hospital. Of these, 81 patients (5%) were aged 40 years at initial diagnosis. The demographics of all 1746 patients with adenocarcinoma are listed in Table 1 . Nine-hundred seven patients (52%) were men, 765 (44%) were never smokers, and the median age of all patients was 65 years (range, 26-93 years). Most patients (98%) had a good Eastern Cooperative Oncology Group PS of 0 or 1 at initial diagnosis; and there were 687 patients (39%) with stage I disease, 132 (8%) with stage II disease, 302 (17%) with stage III disease, and 625 (36%) with stage IV disease. Histologic subtypes of lung adenocarcinoma were determined in 853 patients who underwent surgery, including 22 patients (3%) with adenoma in situ (AIS), 78 (9%) with minimally invasive adenocarcinoma (MIA), 50 (6%) with lepidic predominant adenocarcinoma, 269 (32%) with acinar predominant adenocarcinoma, 242 (28%) with papillary predominant adenocarcinoma, 23 (3%) with micropapillary predominant adenocarcinoma, 106 (13%) with solid predominant adenocarcinoma, and 63 (7%) with invasive mucinous adenocarcinoma (IMA). Among the 81 younger patients who had adenocarcinoma diagnosed at age 40 years, 36 (44%) were men, 36 (44%) were never smokers, and their median age was 36 years (range, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] Original Article years). Patients with stage IV disease were significantly more frequent in this group compared with the older age group (aged >40 years; P < .001). Most patients (96%) had an Eastern Cooperative Oncology Group PS of 0 or 1. There was no significant difference in the distribution of histologic subtypes between the younger and older age groups (P 5 .170), although the solid subtype was identified more frequently in younger patients (29% vs 12%). Figure 1 indicates that screening for EGFR and KRAS mutations was routine for 1149 consecutive patients with adenocarcinoma who were diagnosed between 2009 and 2013. Of these, 527 patients (46%) harbored EGFR mutations, and 111 (10%) carried KRAS mutations. Of 511 patients who had wild-type EGFR/KRAS (2-wt) adenocarcinoma, 352 were screened for ALK translocations, and 62 had ALK translocations identified. Among 129 patients with wild-type EGFR/KRAS/ALK (3-wt) adenocarcinoma who were screened, 9 had HER2 mutations, and 1 had BRAF mutation. After 2014, 597 consecutive patients with adenocarcinoma were screened for EGFR, KRAS, HER2, and BRAF mutations and ALK translocations. Of these, 252 patients (42%) had EGFR mutations, 56 (9%) had KRAS mutations, 14 (2%) had HER2 mutations, 7 (1%) had BRAF mutations, and 41 (7%) had ALK translocations. Furthermore, we experimentally analyzed ROS1 and RET translocations among 46 patients with wild-type EGFR/KRAS/ALK/HER2/BRAF (5-wt) adenocarcinoma who were diagnosed between 2009 and 2015. Three patients had ROS1 translocations identified, and 4 had RET translocations identified. In total, 1081 of 1746 patients with lung adenocarcinoma (62%) harbored some oncogenic GAs. We have summarized the GA status of all patients diagnosed between 2009 and 2015 according to each oncogenic GA examination in Supporting Table 2 (see online supporting information).
GA Screening in Lung Adenocarcinoma
Prevalence of EGFR, KRAS, and ALK in Young Patients With Lung Adenocarcinoma
Among the 81 young patients with adenocarcinoma, ALK translocations and EGFR and KRAS mutations were identified in 33 (41%), 24 (30%), and 2 (2%) patients, respectively (Fig. 2 ). Two patients with wild-type EGFR/KRAS (2-wt) adenocarcinoma were not examined for ALK translocations. The remaining 20 patients (25%) had wildtype EGFR, KRAS mutations and ALK translocation (3-wt). Compared with the older age group, the frequency of ALK translocation was significantly higher in the younger group (41% vs 4%; P < .001), whereas EGFR and KRAS mutations were less frequent in the younger population (EGFR: 30% vs 45%; P 5 .006, KRAS: 2% vs 10%; P 5 .026).
Prevalence of HER2, BRAF, RET, and ROS1 in Young Patients With Lung Adenocarcinoma Figure 3A indicates that 16 of 20 patients (80%) who had 3-wt adenocarcinoma aged 40 years were screened for HER2 and BRAF mutations. HER2 mutations were identified in 4 patients, and no BRAF mutations were identified. The distribution of HER2-mutant, BRAF-mutant, and 5-wt patients differed significantly between the younger and older age groups (P 5 .004) (Fig. 3B) ; the frequency of HER2 mutations among the screened patients with 3-wt adenocarcinomas was significantly higher in the younger group compared with the older group (25% vs 5.3%; P < .001) (Supporting Table 2 ; see online supporting information), whereas there was no significant difference in the frequency of BRAF mutation among the screened patients with 3-wt adenocarcinoma (0% vs 2.2%; P 5 .562) (Supporting Table 2 ; see online supporting information). We also experimentally analyzed RET and ROS1 translocations in 9 of 12 patients (75%) with 5-wt adenocarcinoma aged 40 years. Of the 9 patients screened, 2 patients had RET translocations, and 2 had ROS1 translocations (Fig. 3A) . The frequency of RET and ROS1 translocations in 5-wt screened adenocarcinomas was higher in the younger group compared with the older group (RET: 22.2% vs 5.4%; P 5 .108; ROS1: 22.2% vs 2.7%; P 5 .033) (Supporting Table 2 ; see online supporting information), although RET and ROS1 translocations were examined in smaller numbers among the older group.
In total, 67 of 81 young patients with adenocarcinoma were identified with some oncogenic GAs, and the rate was significantly higher compared with that in the older patients (83% vs 61%; P < .001), as indicated in Figure 4 . Comparing the frequency of driver GAs between the 2 age groups, the likelihood of harboring ALK translocations and HER2 mutations steadily decreased with age, whereas KRAS and BRAF mutations exhibited the opposite trend (Fig. 4) . Table 2 indicates that ALK translocations were significantly more frequent in young patients with stage IV adenocarcinoma than in those with stage I through III adenocarcinoma (P 5 .007). Concerning the other GAs, there was no significant difference in the frequency between stages I through III and stage IV. Accordingly, ALK translocations were identified most frequently in patients with stage IV adenocarcinoma (29 of 58 patients; 50%). Conversely, EGFR mutations were the most common GA among patients with stage I through III adenocarcinoma (9 of 23 patients; 39%). In total, patients with stage IV adenocarcinoma represented a higher percentage of those with some GAs compared with patients who had stage I through III adenocarcinoma, although the difference was not statistically significant (86% vs 74%; P 5 .187).
GA Distribution in Young Patients With Adenocarcinoma According to Stage
EGFR Mutation Status Among Young Patients With Adenocarcinoma
The distribution of EGFR mutation status according to age is provided in Table 3 . Among the patients with EGFR-mutant lung adenocarcinoma, exon 19 deletions were identified more frequently in the younger cohort Figure 1 . This is a Consolidated Standards for Reporting Trials diagram of screening for driver genetic alterations in 1746 patients with adenocarcinoma. ALK indicates anaplastic lymphoma kinase; BRAF, B-raf proto-oncogene, serine/threonine kinase; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; RET, Ret protooncogene; ROS1, ROS proto-oncogene 1, receptor tyrosine kinase.
(75% vs 43%; P 5 .002), as previously reported. [23] [24] [25] In contrast, a leucine-to-arginine codon 858 (L858R) point mutation in exon 21 was less common in the younger group (17% vs 48%; P 5 .002). Of the minor mutations, exon 20 insertion was more frequent in the younger group (8% vs 1%; P 5 .001), whereas the frequency of the remaining minor mutations was similar between the 2 groups.
RFS According to Age and GA Status
We divided 939 patients with stage I through III adenocarcinoma who underwent surgery into 4 subgroups according to age and GA status (aged 40 or >40 years, with or without any GA) and compared RFS among them. Figure 5A indicates that the younger group without GAs had significantly shorter RFS compared with the other subgroups (median RFS, 11.1 months vs not available [NA]; P < .001). There was no significant difference according to age among the patients who had adenocarcinoma with GAs.
OS According to Age and GA Status
We also divided 625 patients with stage IV adenocarcinoma into 4 subgroups according to age and GA status (aged 40 or >40 years, with or without any GA) and compared OS among them (Fig. 5B) . We observed that the younger group without GAs had significantly shorter OS compared with the older age group without GAs (median OS, 8.9 months [95% confidence interval (CI), 3.3-11.0 months] vs 18.4 months [95% CI, 12.3-27.4 months], respectively; P < .001). Together with the RFS analysis, the OS results indicated that the subgroup of younger patients who had adenocarcinomas without GAs had a distinctly worse prognosis compared with that of the older patients without GAs and those who had adenocarcinomas with GAs.
Among the patients who had adenocarcinoma with GAs, there was no difference in OS according to age (40 vs >40 years: 25 (Fig. 6B ).
Multivariate Analysis of RFS and OS
To consider covariates that may affect RFS and OS, we performed multivariate analyses of patients with and without GAs. In the multivariate RFS analysis, stage (P < .001) was a statistically significant factor among 559 patients who had stage I through III adenocarcinoma with GAs. Among 380 patients who had stage I through III adenocarcinoma without GAs, stage (P 5 .008) and age (P 5 .029) were significantly associated with recurrence Figure 4 . The frequency of oncogenic genetic alterations is illustrated according to age. ALK indicates anaplastic lymphoma kinase; BRAF, B-raf proto-oncogene, serine/threonine kinase; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; RET, Ret protooncogene; ROS1, ROS proto-oncogene 1, receptor tyrosine kinase; wt, wild type. Original Article (Table 4 ). In the multivariate OS analysis, PS (P 5 .019) was a statistically significant factor among 377 patients who had stage IV adenocarcinoma with GAs. Among 248 patients who had stage IV adenocarcinoma without GAs, PS (P 5 .008) and age (P 5 .048) were significantly associated with survival. 
DISCUSSION
In this study, we demonstrated that younger age is associated with an increased likelihood of harboring oncogenic GAs in patients with lung adenocarcinoma, and those who were diagnosed at age 40 years were associated with driver GAs significantly more than those who were diagnosed at age >40 years (83% vs 61%, respectively; P < .001). ALK translocations were significantly more frequent in younger patients compared with older patients (41% vs 4%; P < .001), whereas EGFR and KRAS mutations were less frequent in younger patients (EGFR: 30% vs 45%; P 5 .006; KRAS: 2% vs 10%; P 5 .026). Although not all patients were screened for rare GAs, the frequency of HER2 mutations and of ROS1 and RET translocations was much higher in the younger population, suggesting that comprehensive oncogenic GA analysis is strongly recommended for young patients with adenocarcinomas. To the best of our knowledge, this study is the first report elucidating the finding that ALK, ROS1, and RET translocations and HER2 mutations are not "rare" oncogenic GAs in this population. It is noteworthy that an ALK translocation was the most common driver oncogene identified in young patients with adenocarcinoma, and most were diagnosed at an advanced stage. Recent data have suggested that ALK translocations are associated with the onset of lung cancer in young patients. 6, 26, 27 There are striking similarities between our findings and 2 previous cohorts with regard to the distribution of ALK translocations and EGFR mutations among young patients with adenocarcinoma. 26, 27 Nagashima et al reported that 5 of 12 patients (42%) carried an ALK translocation, and 4 of 12 (33%) harbored EGFR mutations among those with advanced-stage adenocarcinoma aged <40 years, although the sample size was small. Gitlitz et al screened comprehensive genomic profiling data based on the Foundation One Assay and demonstrated that 22 of 50 patients (44%) carried ALK translocations, and 13 of 50 (26%) harbored EGFR mutations among patients aged <40 years who had stage IV adenocarcinomas. Moreover, ALK translocations were identified predominantly in patients who had advanced disease stage in our study, indicating that ALK translocations may confer more malignant potential, as previously reported in several studies. 28, 29 These results suggest that approximately two-thirds of young patients with adenocarcinoma have the opportunity to gain a survival benefit from approved ALK or EGFR tyrosine kinase inhibitors.
Patients who had metastatic adenocarcinoma with GAs, as expected, had significantly better OS compared with those who did not have GAs, probably because of molecularly targeted therapies. Focusing on the patients who had metastatic adenocarcinoma without GAs, there was a significant discrepancy in OS between those diagnosed at age 40 years versus age >40 years (OS, 8.9 vs 18.4 months; P < .001), whereas there was no significant difference in OS according to age among those who had adenocarcinoma with GAs. Consistent with these results, the younger patients who had stage I through III adenocarcinoma without GAs and underwent surgery also had significantly worse RFS compared with the older patients without GAs and those who had adenocarcinoma with GAs. These findings indicate that a subgroup of young patients who have adenocarcinomas without GAs have unique tumor biology, which potentially confers rapid progression or early recurrence. Previous reports have also demonstrated that the survival of young patients with NSCLC is worse compared with that of other age groups 30 ; however, comparisons between those with and without GAs have not been analyzed. Although we did not perform additional genetic analyses other than those for clinically targetable GAs, the significantly higher prevalence of tumor protein 53 (TP53) mutations was previously reported in young patients with lung adenocarcinoma, 24 which may explain the worse prognosis in this population. Further studies are warranted to elucidate the underlying mechanisms that explain the more aggressive biology of adenocarcinoma without GA in younger patients.
HER2 mutations were the most frequent GA among patients aged 40 years who had 3-wt (wild-type EGFR/ ALK/KRAS) adenocarcinomas. Several studies have demonstrated that approximately 1% to 2% of patients with lung adenocarcinoma harbor a mutation in exon 20 of HER2. [31] [32] [33] In our study, HER2 mutations were identified in 2.3% of patients with adenocarcinoma in both age groups (14 of 597), compatible with previous reports. The positive rate of HER2 mutations among screened patients who had 3-wt adenocarcinoma screened was significantly higher in patients aged 40 years compared with those aged >40 years (25% vs 5.3%; P < .001). Furthermore, we experimentally analyzed ROS1 and RET translocations in patients who had 5-wt (wild-type EGFR/ ALK/KRAS/HER2/BRAF) adenocarcinomas and identified 3 who had ROS1-rearranged adenocarcinoma (7%) and 4 who had RET-rearranged adenocarcinoma (9%) of the 46 screened patients. ROS1 and RET translocations reportedly are detected in <2% of patients with NSCLC and are identified predominantly in younger patients with adenocarcinoma who have no smoking history. 5, 6, 22, 34 Surprisingly, ROS1 or RET translocations were identified Original Article in 4 of the 9 screened 5-wt patients aged 40 years. Together, when limiting the analysis to patients with EGFR/ ALK/KRAS wild-type adenocarcinomas and further focusing on the younger population, HER2 mutations and ROS1 and RET translocations are not "rare" oncogenic GAs, and patients should be routinely screened for these GAs, because matched, targeted therapies are currently promising for prolonging prognosis.
For the remaining younger patients who had all wild-type adenocarcinomas, a new, yet unknown oncogenic GA may be hiding behind clinical genotype screening, because the younger population represented a "genomically enriched subtype," referring to our results and previous studies. 26, 27, 30 For example, EGFR-RAD51 fusion and EGFR kinase domain duplication have recently been reported as actionable EGFR mutations, which were discovered by chance when screening young patients with adenocarcinoma by deep sequencing. 35, 36 A further comprehensive analysis that includes next-generation sequencing will be required to understand the unique molecular biology of young patients with adenocarcinomas. Recently, a prospective study to test the utility of targeted nextgeneration sequencing for young patients with lung cancer (aged <40 years at diagnosis) has been initiated through a collaboration between the Addario Lung Cancer Medical Institute and Foundation Medicine (National Clinical Trials identifier NCT02273336; www.clinicaltrials.gov).
In interpreting these findings, several limitations inherent to this study must be considered. The data used in this study were limited given its retrospective nature and limited comprehensive data, especially on rare GAs. The patients included in this study are also drawn from a single institution and thus are subject to referral bias. Driver GA analysis was performed based on the institutional standard of care for all patients, and the young population had more opportunities for screening of rare GAs at each physician's discretion. The limitation of tissue availability from small biopsies also contributed to the heterogeneity for comprehensive rare GA analysis. On the basis of mutual exclusivity among driver oncogenes, the patients who were diagnosed between 2009 and 2013 were not examined for the other GAs once a single GA was identified. Thus, not all patients in this study underwent identical genotyping, and genotyping data were not completely comprehensive for all patients.
In conclusion, young patients with lung adenocarcinoma had a uniquely high incidence of driver GAs. The prognosis for this population with GAs was compatible with that for the older age group with GAs. Conversely, younger patients without GAs had a significantly worse prognosis compared with older patients without GAs. Accordingly, young patients with adenocarcinoma may be prime candidates for precision medicine strategies, because they tend to have more GAs that can be treated with existing targeted therapies, leading to a compatible prognosis.
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